Testing blood-clone risk to prevent chemotherapy complications
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at a specific genetic/production change in blood-forming cells (“clonal hematopoiesis”) to understand who is more likely to have complications from lymphoma chemotherapy. It may help doctors predict risk and possibly reduce harmful side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a lymphoma diagnosis (such as DLBCL, follicular, Hodgkin, CLL/SLL, or other listed types).
- You are starting your first or second course of chemotherapy for lymphoma (sometimes with rituximab).
- You do not have a known blood cancer of myeloid origin (a “myeloid neoplasm”).
- Your lymphocyte count is not too high (must be 10 × 10^9/L or less).
- Your kidneys and liver function are controlled enough for chemotherapy (not significantly above lab limits).
- You do not have HIV and do not have a current (active) infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This trial tests a modified chemotherapy conditioning regimen (called improved BEAM) before your own stem cell transplant for non-Hodgkin lymphoma. The goal is to see if the new regimen is safer and works as well as the standard approach, possibly with fewer side effects.
This study tests whether using a special blood test (ctDNA) to guide targeted therapy can improve outcomes for people with a type of lymphoma called DLBCL. If you qualify, you may receive a standard chemo-immunotherapy regimen (R-CHOP) possibly combined with other drugs, and your treatment plan may be adjusted based on your ctDNA levels.
This study tests a new treatment combination (CD-RCHOP, likely a form of chemotherapy with an antibody) for people with a high-risk type of diffuse large B-cell lymphoma that has certain genetic changes (TP53 mutation and 17p deletion). It aims to see if this approach is safe and effective for this specific group.
This study looks for early signs of blood cancers in people who have them or are at higher risk, like family members or older adults. It aims to find cancer sooner, which may lead to better outcomes.
This trial studies the best way to use an early (frontline) stem cell transplant for high-risk, CD20-positive diffuse large B-cell lymphoma (DLBCL). It aims to improve outcomes by comparing treatment approaches designed for people with a higher risk score.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.